Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, 12700 E. 19th Avenue, RC2, B131, Aurora, CO 80045, USA.
Pulmonary and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, 12700 E. 19th Avenue, RC2, B131, Aurora, CO 80045, USA.
Cardiovasc Res. 2018 Mar 15;114(4):551-564. doi: 10.1093/cvr/cvy004.
Pulmonary hypertension (PH) is the end result of interaction between pulmonary vascular tone and a complex series of cellular and molecular events termed 'vascular remodelling'. The remodelling process, which can involve the entirety of pulmonary arterial vasculature, almost universally involves medial thickening, driven by increased numbers and hypertrophy of its principal cellular constituent, smooth muscle cells (SMCs). It is noted, however that SMCs comprise heterogeneous populations of cells, which can exhibit markedly different proliferative, inflammatory, and extracellular matrix production changes during remodelling. We further consider that these functional changes in SMCs of different phenotype and their role in PH are dynamic and may undergo significant changes over time (which we will refer to as cellular plasticity); no single property can account for the complexity of the contribution of SMC to pulmonary vascular remodelling. Thus, the approaches used to pharmacologically manipulate PH by targeting the SMC phenotype(s) must take into account processes that underlie dominant phenotypes that drive the disease. We present evidence for time- and location-specific changes in SMC proliferation in various animal models of PH; we highlight the transient nature (rather than continuous) of SMC proliferation, emphasizing that the heterogenic SMC populations that reside in different locations along the pulmonary vascular tree exhibit distinct responses to the stresses associated with the development of PH. We also consider that cells that have often been termed 'SMCs' may arise from many origins, including endothelial cells, fibroblasts and resident or circulating progenitors, and thus may contribute via distinct signalling pathways to the remodelling process. Ultimately, PH is characterized by long-lived, apoptosis-resistant SMC. In line with this key pathogenic characteristic, we address the acquisition of a pro-inflammatory phenotype by SMC that is essential to the development of PH. We present evidence that metabolic alterations akin to those observed in cancer cells (cytoplasmic and mitochondrial) directly contribute to the phenotype of the SM and SM-like cells involved in PH. Finally, we raise the possibility that SMCs transition from a proliferative to a senescent, pro-inflammatory and metabolically active phenotype over time.
肺动脉高压(PH)是肺血管张力与一系列复杂的细胞和分子事件(称为“血管重构”)相互作用的最终结果。重构过程几乎普遍涉及中膜增厚,这是由其主要细胞成分——平滑肌细胞(SMC)的数量增加和肥大所驱动的。然而,值得注意的是,SMC 由具有不同表型的异质细胞群组成,在重构过程中,这些细胞群的增殖、炎症和细胞外基质产生变化可显著不同。我们进一步认为,这些不同表型的 SMC 的功能变化及其在 PH 中的作用是动态的,可能随时间发生显著变化(我们将其称为细胞可塑性);没有单一特性可以解释 SMC 对肺血管重构的复杂性贡献。因此,通过针对 SMC 表型来药理学地干预 PH 的方法必须考虑到驱动疾病的优势表型的潜在过程。我们提供了在各种 PH 动物模型中 SMC 增殖的时间和位置特异性变化的证据;我们强调了 SMC 增殖的短暂性(而非持续性),并强调了存在于肺血管树不同位置的异质 SMC 群对与 PH 发展相关的应激具有不同的反应。我们还认为,通常被称为“SMC”的细胞可能起源于许多来源,包括内皮细胞、成纤维细胞和驻留或循环祖细胞,因此可能通过不同的信号通路对重构过程做出贡献。最终,PH 的特征是存在长寿、抗凋亡的 SMC。与这一关键致病特征一致,我们探讨了 SMC 获得促炎表型的问题,这对 PH 的发展至关重要。我们提供的证据表明,类似于癌细胞(细胞质和线粒体)中观察到的代谢改变直接导致了参与 PH 的 SM 和 SM 样细胞的表型。最后,我们提出了这样一种可能性,即 SMC 随着时间的推移从增殖状态过渡到衰老、促炎和代谢活跃的表型。